Highly concentrated omega-3 fatty acid ethyl esters by urea complexation and molecular distillation

2018 ◽  
Vol 99 (2) ◽  
pp. 877-884 ◽  
Author(s):  
Leisa M Magallanes ◽  
Lorena V Tarditto ◽  
Nelson R Grosso ◽  
María C Pramparo ◽  
María F Gayol
Keyword(s):  
Fatty Acid ◽  
Molecular Distillation ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Omega 3 Fatty Acid ◽  
Urea Complexation

Breast Cancer Genetic and Molecular Subtype Impacts Response to Omega-3 Fatty Acid Ethyl Esters

2016 ◽  
Vol 68 (6) ◽  
pp. 1021-1033 ◽  
Author(s):  
Ching Hui Chen ◽  
Carol Fabian ◽  
Stephen Hursting ◽  
Linda A. deGraffenried
Keyword(s):  
Breast Cancer ◽  
Fatty Acid ◽  
Molecular Subtype ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Cancer Genetic ◽  
Omega 3 Fatty Acid

scholarly journals Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters

2012 ◽  
Vol 6 (1) ◽  
pp. 122-125 ◽  
Author(s):  
Vasilios G Athyros ◽  
Dimitri P Mikhailidis
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Fatty Acid ◽  
Kidney Disease ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Omega 3 Fatty Acid ◽  
Mixed Hyperlipidemia

This is a case report that describes a 67-year-old woman with mixed hyperlipidemia and diabetic nephropathy. She was initially prescribed a combination of simvastatin plus gemfibrozil by her general practitioner (GP). When referred to our cardiovascular unit, we further diagnosed the patient to have mixed hyperlipidemia and rhabdomyolysis. Because of concerns with her chronic kidney disease (CKD), we temporarily stopped all her drug treatments and started insulin treatment for her type 2 diabetes (T2D). A month later when her T2D was stabilised, we prescribed atorvastatin and an omega-3 fatty acid ethyl ester supplement to treat her hypertriglyceridemia. Within two months her blood lipids were within the recommended range. In patients with stage 3–5 CKD, it is not advisable to prescribe the fibrate gemfibrozil, particularly in combination with a statin that is metabolised predominantly in the kidneys. To minimise adverse events without compromise on efficacy, we used a combination of omega-3 fatty acid ethyl esters, which are not metabolised in the kidneys, with a statin that is minimally metabolised in the kidneys for the treatment of her hyperlipidemia.

Triglyceride-Lowering Effect of Omega-3 Fatty Acid Ethyl Esters Using Advanced Lipid Technologiestm (ALT ® ) formulations Under Fasting Conditions

2017 ◽  
Vol 11 (3) ◽  
pp. 828-829
Author(s):  
Miguel Lopez-Toledano ◽  
Ahmed Daak ◽  
Thorsteinn Thorsteinsson ◽  
Frederick Sancilio ◽  
Adrian Rabinowicz
Keyword(s):  
Fatty Acid ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Omega 3 Fatty Acid ◽  
Lowering Effect

scholarly journals Omega-3 fatty acid ethyl esters do not improve clopidogrel associated P2Y12 inhibition in stroke patients

2015 ◽  
Vol 7 (1) ◽  
Author(s):  
Ping Li ◽  
Haris Kamal ◽  
Melissa Baxter ◽  
Bijal K. Mehta
Keyword(s):  
Fatty Acid ◽  
Cerebrovascular Disease ◽  
Cerebral Aneurysms ◽  
Platelet Inhibition ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Omega 3 Fatty Acid ◽  
Platelet Receptor ◽  
At Home

The specific action of omega-3 fatty acid ethyl esters (OFA) in preventing cerebrovascular disease remains unknown, but research has demonstrated multiple possible mechanisms. In addition to altering lipid profiles, OFA may inhibit platelet aggregation. Clopidogrel inhibits platelets via the P2Y12 receptor. OFA may alter clopidogrel-associated platelet-inhibition via a possible combined effect on P2Y12 inhibition. To determine if OFA affects clopidogrel associated P2Y12 platelet receptor inhibition by comparing the percentage of responders in patients with cerebrovascular disease who were taking clopidogrel with or without OFA. We retrospectively reviewed data from adult patients with cerebrovascular disease or cerebral aneurysms and taking clopidogrel, who were seen at a single hospital between March 2010 to September 2011. We included 438 subjects in the study. For the 67 subjects who received loading doses of both clopidogrel and OFA, 71.6% had a P2Y12 inhibition response more than 20%, which is considered a positive response. For the 55 subjects who received just clopidogrel load, 67.2% of subjects were responders. There were 70.4% responders in the 274 subjects who were taking 75 mg of clopidogrel alone at home, and 73.8% responders in the 42 subjects who were taking both clopidogrel and OFA at home. However, these percentage differences were not statistically significant. This study did not find additional P2Y12 platelet inhibition when patients were given OFA, either given as a loading dose or taking it daily.

scholarly journals Reduction of circulating FABP4 level by treatment with omega-3 fatty acid ethyl esters

2016 ◽  
Vol 15 (1) ◽  
Author(s):  
Masato Furuhashi ◽  
Shinya Hiramitsu ◽  
Tomohiro Mita ◽  
Akina Omori ◽  
Takahiro Fuseya ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Omega 3 Fatty Acid
Sign in / Sign up

Export Citation Format

Share Document